Ketim Technologies Joins Brisbane MedTech Global Accelerator to Fast-Track Global Expansion

29 July

Brisbane, Australia – July 29, 2025 – Ketim Technologies, a leader in biomarker-based diagnostics for perinatal mental health, is proud to announce its selection for the Year 4 Cohort of the Brisbane Economic Development Agency’s (BEDA) MedTech Global Accelerator Program.

The flagship six-month program, delivered in partnership with Life Science Nation, provides tailored support for early-stage health technology companies with high-growth potential. As part of the cohort, Ketim Technologies will receive strategic mentoring, global market readiness training, and targeted investor engagement, culminating in a high-profile pitch to international investors at J.P. Morgan Healthcare Week in San Francisco in January 2026.

Participation in the accelerator marks a significant milestone in Ketim Technologies’ global expansion strategy. The company, co-led in this initiative by Founder and CEO Dr. Clarissa Yates and Director of AI and Data Science Dr. Maciej Trzaskowski, is advancing development of the world’s first clinical blood test for the early detection of postpartum depression, underpinned by patented biomarker technology and AI-driven analytics.

“We are honoured to join such an outstanding group of innovators in the BEDA MedTech Global Accelerator,” said Dr. Yates. “This program will accelerate our pathway to international markets, strengthen our global investor network, and position Ketim Technologies to make a lasting impact on maternal mental health worldwide.”

For media inquiries, please contact:
Dr. Clarissa Yates
CEO, Ketim Technologies
clarissa.yates@ketim.com.au